0001415889-24-016259.txt : 20240610
0001415889-24-016259.hdr.sgml : 20240610
20240610175554
ACCESSION NUMBER: 0001415889-24-016259
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240607
FILED AS OF DATE: 20240610
DATE AS OF CHANGE: 20240610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Masoud Maher
CENTRAL INDEX KEY: 0001874571
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40674
FILM NUMBER: 241033980
MAIL ADDRESS:
STREET 1: C/O MAXCYTE, INC.
STREET 2: 22 FIRSTFIELD ROAD, SUITE 110
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MAXCYTE, INC.
CENTRAL INDEX KEY: 0001287098
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 522210438
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9713 KEY WEST AVENUE,
STREET 2: SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-517-5556
MAIL ADDRESS:
STREET 1: 9713 KEY WEST AVENUE,
STREET 2: SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: MAXCYTE INC
DATE OF NAME CHANGE: 20040415
4
1
form4-06102024_090649.xml
X0508
4
2024-06-07
0001287098
MAXCYTE, INC.
MXCT
0001874571
Masoud Maher
C/O MAXCYTE, INC.
9713 KEY WEST AVENUE, SUITE 400
ROCKVILLE
MD
20850
true
true
false
false
President and CEO
0
Common Stock
2024-06-07
4
P
0
29557
4.866
A
29557
D
Common Stock
2024-06-10
4
P
0
70443
4.901
A
100000
D
The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.84 to $4.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.77 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Brian Leaf, Attorney-in-Fact
2024-06-10